The sub-questions all reflect the same underlying approval process and are highly correlated, so a weighted average centered on the PDUFA-date approval likelihood best captures the answer, adjusted by CRL risk and clinical strength.
## Cross-Market Signals ### Polymarket - "Will Russia capture all of Stepnohirsk by September 30, 2026?" → Yes: 0.11, Volume: $354.5K
1. [sq1 | article_search | STRONG cred 88 | UP | DATED] Viridian says FDA accepted veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date. 2. [sq3 | description | MODERATE cred 80 | UP | DATED] Tepezza was the first FDA-approved TED treatment (Jan 2020), establishing an approval pathway and validated mechanism for this indication. 3. [sq2 | article_search | MODERATE cred 78 | NEUTRAL | RECENT] FDA Commissioner Marty Makary is resigning after a rocky 13-month tenure amid management complaints. 4. [sq2 | article_search | MODERATE cred 65 | DOWN | RECENT] FDA watchers warn of 'chaos,' staff hemorrhaging, and risk of regulatory delays inside the agency. 5. [sq2 | article_search | MODERATE cred 68 | DOWN | RECENT] FDA denied or discouraged at least eight drugs in the past year per RTW Investments, citing evidence concerns. 6. [sq3 | article_search | WEAK cred 40 | NEUTRAL | VERY_RECENT] No article specifically referencing veligrotug clinical trial data, safety holds, or regulatory status was found in the research set. 7. [sq1 | article_search | WEAK cred 45 | NEUTRAL | VERY_RECENT] No news of veligrotug approval, CRL, or delay appeared in articles through June 19, 2026. ## Cross-Market Signals ### Polymarket - "Will Russia capture all of Stepnohirsk by September 30, 2026?" → Yes: 0.11, Volume: $354.5K Information gaps: - No base rate for on-time PDUFA approval under Priority Review - No veligrotug pivotal trial (THRIVE) efficacy/safety results - No FDA advisory committee scheduling info for veligrotug - No confirmation of approval/CRL after June 30 PDUFA date Key uncertainties: - Whether FDA staff turnover causes a delay past Sept 1 - CRL risk given recent FDA rejection streak - Impact of Makary departure on review timelines - Whether manufacturing/inspection issues arise
You are an elite superforecaster using Tetlock-style Fermi decomposition. Estimate each sub-question INDEPENDENTLY, then provide a holistic estimate. The pipeline will mathematically recombine the sub-question estimates — your job is to give the most accurate per-component probabilities.
## Question
Will FDA approve veligrotug for thyroid eye disease before September 1, 2026?
## Description / Resolution Criteria
## Description
Viridian [says](https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Announces-BLA-Acceptance-and-Priority-Review-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease/default.aspx?utm_source=chatgpt.com) FDA accepted the veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date. A similar TED approval resolved publicly when FDA approved Tepezza, the first treatment for thyroid eye disease, in January 2020.
`{"format": "bot_tournament_question", "info": {"hash_id": "4f4f194d04ce2123", "sheet_id": "46"}}`
## Resolution Criteria
This question resolves as Yes if FDA approves veligrotug, VRDN-001, or the same active biologic for any thyroid eye disease indication before September 1, 2026. It resolves as No if FDA issues a CRL, the application is withdrawn, or no approval is publicly confirmed before September 1, 2026.
## Sub-question decomposition
- (w=0.50) Will the FDA approve veligrotug on or before its June 30, 2026 PDUFA target action date? — Priority Review BLAs with accepted applications are most likely to be approved at or near the PDUFA date; this is the ce
- (w=0.30) Will veligrotug avoid a Complete Response Letter, withdrawal, or major delay before September 1, 2026? — The main failure modes are a CRL or withdrawal; ruling these out supports a Yes.
- (w=0.20) Has veligrotug's clinical/regulatory record (pivotal trial success, no safety holds) remained strong and on track? — Strong Phase 3 data and clean regulatory status increase approval odds; weak signals would raise CRL risk.
Combination rule: **weighted_average**
## Synthesized evidence
1. [sq1 | article_search | STRONG cred 88 | UP | DATED] Viridian says FDA accepted veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date.
2. [sq3 | description | MODERATE cred 80 | UP | DATED] Tepezza was the first FDA-approved TED treatment (Jan 2020), establishing an approval pathway and validated mechanism for this indication.
3. [sq2 | article_search | MODERATE cred 78 | NEUTRAL | RECENT] FDA Commissioner Marty Makary is resigning after a rocky 13-month tenure amid management complaints.
4. [sq2 | article_search | MODERATE cred 65 | DOWN | RECENT] FDA watchers warn of 'chaos,' staff hemorrhaging, and risk of regulatory delays inside the agency.
5. [sq2 | article_search | MODERATE cred 68 | DOWN | RECENT] FDA denied or discouraged at least eight drugs in the past year per RTW Investments, citing evidence concerns.
6. [sq3 | article_search | WEAK cred 40 | NEUTRAL | VERY_RECENT] No article specifically referencing veligrotug clinical trial data, safety holds, or regulatory status was found in the research set.
7. [sq1 | article_search | WEAK cred 45 | NEUTRAL | VERY_RECENT] No news of veligrotug approval, CRL, or delay appeared in articles through June 19, 2026.
## Cross-Market Signals
### Polymarket
- "Will Russia capture all of Stepnohirsk by September 30, 2026?" → Yes: 0.11, Volume: $354.5K
Information gaps:
- No base rate for on-time PDUFA approval under Priority Review
- No veligrotug pivotal trial (THRIVE) efficacy/safety results
- No FDA advisory committee scheduling info for veligrotug
- No confirmation of approval/CRL after June 30 PDUFA date
Key uncertainties:
- Whether FDA staff turnover causes a delay past Sept 1
- CRL risk given recent FDA rejection streak
- Impact of Makary departure on review timelines
- Whether manufacturing/inspection issues arise
## Required pre-forecast walkthrough
Before giving probabilities, walk through these explicitly:
(a) The time left until the question resolves.
(b) The status quo outcome — what happens if nothing changes from today.
(c) A brief scenario that results in NO.
(d) A brief scenario that results in YES.
## Calibration guidance
- **Estimate each sub-question in isolation.** Do not let your answer to one sub-question anchor your answer to another. This is the core of Fermi decomposition — independence forces more careful reasoning per factor.
- **Anchor on the status quo.** Require strong specific evidence to move far from it.
- 0.05 / 0.95 require strong, multi-source evidence. Avoid >0.97 or <0.03 unless the outcome is already settled or near-tautological — overconfident misses are punished heavily by the log score.
- **Anchor on prediction markets.** If liquid market prices (Polymarket / Kalshi) or a community forecast appear in the evidence, treat them as a strong, well-calibrated prior. Your final estimate should rarely sit more than ~15 percentage points from a liquid market on the SAME question — move further only with specific evidence the market lacks.
- **Treat research as fallible, not ground truth.** A single-source or "very recent" claim — especially one the evidence flags as unverified, possibly AI-generated, or low-credibility — must not drive you to near-certainty. When a load-bearing fact is unverified, keep at least 10-15% on the chance it is wrong.
- **Also provide a holistic estimate** — your overall gut feeling about the main question, BEFORE you see the mathematical combination. This serves as a sanity check: if the Fermi result and holistic estimate diverge wildly, something is wrong.
## Output
Return ONLY valid JSON, no markdown fences:
{
"rationale": "<address (a) (b) (c) (d) above — 5-8 sentences total>",
"sub_question_estimates": {
"sq1": <float in [0.01, 0.99]>,
"sq2": <float in [0.01, 0.99]>,
"sq3": <float in [0.01, 0.99]>
},
"holistic_p_yes": <float in [0.01, 0.99] — your overall estimate ignoring the decomposition>,
"what_would_change_my_mind": "<1-2 sentences: what new info would push you above 70% or below 30%>"
}
{
"forecast": {
"combination_logic": "weighted_average",
"evidence_brief": "1. [sq1 | article_search | STRONG cred 88 | UP | DATED] Viridian says FDA accepted veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date.\n2. [sq3 | description | MODERATE cred 80 | UP | DATED] Tepezza was the first FDA-approved TED treatment (Jan 2020), establishing an approval pathway and validated mechanism for this indication.\n3. [sq2 | article_search | MODERATE cred 78 | NEUTRAL | RECENT] FDA Commissioner Marty Makary is resigning after a rocky 13-month tenure amid management complaints.\n4. [sq2 | article_search | MODERATE cred 65 | DOWN | RECENT] FDA watchers warn of \u0027chaos,\u0027 staff hemorrhaging, and risk of regulatory delays inside the agency.\n5. [sq2 | article_search | MODERATE cred 68 | DOWN | RECENT] FDA denied or discouraged at least eight drugs in the past year per RTW Investments, citing evidence concerns.\n6. [sq3 | article_search | WEAK cred 40 | NEUTRAL | VERY_RECENT] No article specifically referencing veligrotug clinical trial data, safety holds, or regulatory status was found in the research set.\n7. [sq1 | article_search | WEAK cred 45 | NEUTRAL | VERY_RECENT] No news of veligrotug approval, CRL, or delay appeared in articles through June 19, 2026.\n\n## Cross-Market Signals\n\n### Polymarket\n- \"Will Russia capture all of Stepnohirsk by September 30, 2026?\" \u2192 Yes: 0.11, Volume: $354.5K\n\nInformation gaps:\n - No base rate for on-time PDUFA approval under Priority Review\n - No veligrotug pivotal trial (THRIVE) efficacy/safety results\n - No FDA advisory committee scheduling info for veligrotug\n - No confirmation of approval/CRL after June 30 PDUFA date\n\nKey uncertainties:\n - Whether FDA staff turnover causes a delay past Sept 1\n - CRL risk given recent FDA rejection streak\n - Impact of Makary departure on review timelines\n - Whether manufacturing/inspection issues arise",
"forecast_prompt": "You are an elite superforecaster using Tetlock-style Fermi decomposition. Estimate each sub-question INDEPENDENTLY, then provide a holistic estimate. The pipeline will mathematically recombine the sub-question estimates \u2014 your job is to give the most accurate per-component probabilities.\n\n## Question\nWill FDA approve veligrotug for thyroid eye disease before September 1, 2026?\n\n## Description / Resolution Criteria\n## Description\nViridian [says](https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Announces-BLA-Acceptance-and-Priority-Review-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease/default.aspx?utm_source=chatgpt.com) FDA accepted the veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date. A similar TED approval resolved publicly when FDA approved Tepezza, the first treatment for thyroid eye disease, in January 2020.\n\n`{\"format\": \"bot_tournament_question\", \"info\": {\"hash_id\": \"4f4f194d04ce2123\", \"sheet_id\": \"46\"}}`\n\n## Resolution Criteria\nThis question resolves as Yes if FDA approves veligrotug, VRDN-001, or the same active biologic for any thyroid eye disease indication before September 1, 2026. It resolves as No if FDA issues a CRL, the application is withdrawn, or no approval is publicly confirmed before September 1, 2026.\n\n## Sub-question decomposition\n- (w=0.50) Will the FDA approve veligrotug on or before its June 30, 2026 PDUFA target action date? \u2014 Priority Review BLAs with accepted applications are most likely to be approved at or near the PDUFA date; this is the ce\n- (w=0.30) Will veligrotug avoid a Complete Response Letter, withdrawal, or major delay before September 1, 2026? \u2014 The main failure modes are a CRL or withdrawal; ruling these out supports a Yes.\n- (w=0.20) Has veligrotug\u0027s clinical/regulatory record (pivotal trial success, no safety holds) remained strong and on track? \u2014 Strong Phase 3 data and clean regulatory status increase approval odds; weak signals would raise CRL risk.\n\nCombination rule: **weighted_average**\n\n## Synthesized evidence\n1. [sq1 | article_search | STRONG cred 88 | UP | DATED] Viridian says FDA accepted veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date.\n2. [sq3 | description | MODERATE cred 80 | UP | DATED] Tepezza was the first FDA-approved TED treatment (Jan 2020), establishing an approval pathway and validated mechanism for this indication.\n3. [sq2 | article_search | MODERATE cred 78 | NEUTRAL | RECENT] FDA Commissioner Marty Makary is resigning after a rocky 13-month tenure amid management complaints.\n4. [sq2 | article_search | MODERATE cred 65 | DOWN | RECENT] FDA watchers warn of \u0027chaos,\u0027 staff hemorrhaging, and risk of regulatory delays inside the agency.\n5. [sq2 | article_search | MODERATE cred 68 | DOWN | RECENT] FDA denied or discouraged at least eight drugs in the past year per RTW Investments, citing evidence concerns.\n6. [sq3 | article_search | WEAK cred 40 | NEUTRAL | VERY_RECENT] No article specifically referencing veligrotug clinical trial data, safety holds, or regulatory status was found in the research set.\n7. [sq1 | article_search | WEAK cred 45 | NEUTRAL | VERY_RECENT] No news of veligrotug approval, CRL, or delay appeared in articles through June 19, 2026.\n\n## Cross-Market Signals\n\n### Polymarket\n- \"Will Russia capture all of Stepnohirsk by September 30, 2026?\" \u2192 Yes: 0.11, Volume: $354.5K\n\nInformation gaps:\n - No base rate for on-time PDUFA approval under Priority Review\n - No veligrotug pivotal trial (THRIVE) efficacy/safety results\n - No FDA advisory committee scheduling info for veligrotug\n - No confirmation of approval/CRL after June 30 PDUFA date\n\nKey uncertainties:\n - Whether FDA staff turnover causes a delay past Sept 1\n - CRL risk given recent FDA rejection streak\n - Impact of Makary departure on review timelines\n - Whether manufacturing/inspection issues arise\n\n## Required pre-forecast walkthrough\n\nBefore giving probabilities, walk through these explicitly:\n (a) The time left until the question resolves.\n (b) The status quo outcome \u2014 what happens if nothing changes from today.\n (c) A brief scenario that results in NO.\n (d) A brief scenario that results in YES.\n\n## Calibration guidance\n\n- **Estimate each sub-question in isolation.** Do not let your answer to one sub-question anchor your answer to another. This is the core of Fermi decomposition \u2014 independence forces more careful reasoning per factor.\n- **Anchor on the status quo.** Require strong specific evidence to move far from it.\n- 0.05 / 0.95 require strong, multi-source evidence. Avoid \u003e0.97 or \u003c0.03 unless the outcome is already settled or near-tautological \u2014 overconfident misses are punished heavily by the log score.\n- **Anchor on prediction markets.** If liquid market prices (Polymarket / Kalshi) or a community forecast appear in the evidence, treat them as a strong, well-calibrated prior. Your final estimate should rarely sit more than ~15 percentage points from a liquid market on the SAME question \u2014 move further only with specific evidence the market lacks.\n- **Treat research as fallible, not ground truth.** A single-source or \"very recent\" claim \u2014 especially one the evidence flags as unverified, possibly AI-generated, or low-credibility \u2014 must not drive you to near-certainty. When a load-bearing fact is unverified, keep at least 10-15% on the chance it is wrong.\n- **Also provide a holistic estimate** \u2014 your overall gut feeling about the main question, BEFORE you see the mathematical combination. This serves as a sanity check: if the Fermi result and holistic estimate diverge wildly, something is wrong.\n\n## Output\n\nReturn ONLY valid JSON, no markdown fences:\n\n{\n \"rationale\": \"\u003caddress (a) (b) (c) (d) above \u2014 5-8 sentences total\u003e\",\n \"sub_question_estimates\": {\n \"sq1\": \u003cfloat in [0.01, 0.99]\u003e,\n \"sq2\": \u003cfloat in [0.01, 0.99]\u003e,\n \"sq3\": \u003cfloat in [0.01, 0.99]\u003e\n },\n \"holistic_p_yes\": \u003cfloat in [0.01, 0.99] \u2014 your overall estimate ignoring the decomposition\u003e,\n \"what_would_change_my_mind\": \"\u003c1-2 sentences: what new info would push you above 70% or below 30%\u003e\"\n}\n",
"holistic_p_yes": 0.8,
"models": [
"opus"
],
"p_yes": 0.7808,
"rationale": "(a) The research horizon runs through ~June 19, 2026, with resolution by Sept 1, 2026 \u2014 roughly two months past the June 30 PDUFA date, giving a buffer for slightly-late approvals to still count. (b) Status quo: an accepted Priority Review BLA backed by positive THRIVE Phase 3 data points toward approval at or near PDUFA; most accepted priority BLAs are approved. (c) NO scenario: FDA issues a CRL (citing manufacturing/inspection or evidence concerns amid the recent rejection streak) or staff turmoil/leadership vacuum from the Makary departure pushes the action date materially past Sept 1. (d) YES scenario: FDA approves on or shortly after June 30, 2026, consistent with the validated TED mechanism (Tepezza precedent) and clean clinical record. The recent FDA chaos and rejection-streak evidence is a real but modest drag; the validated mechanism and priority review are stronger positives. No specific veligrotug-negative signal appeared in research.",
"sub_question_estimates": {
"sq1": 0.7,
"sq2": 0.82,
"sq3": 0.86
},
"what_would_change_my_mind": "Confirmation of approval (or CRL) after June 30, or news of an FDA advisory committee, manufacturing inspection problem, or formal delay would move me sharply above 70% or below 30%."
},
"plan": {
"combination_logic": "weighted_average",
"domain": "health",
"n_sub_qs": 3,
"n_tools": 4,
"reasoning_approach": "The sub-questions all reflect the same underlying approval process and are highly correlated, so a weighted average centered on the PDUFA-date approval likelihood best captures the answer, adjusted by CRL risk and clinical strength.",
"sub_questions": [
{
"id": "sq1",
"question": "Will the FDA approve veligrotug on or before its June 30, 2026 PDUFA target action date?",
"rationale": "Priority Review BLAs with accepted applications are most likely to be approved at or near the PDUFA date; this is the central driver.",
"weight": 0.5
},
{
"id": "sq2",
"question": "Will veligrotug avoid a Complete Response Letter, withdrawal, or major delay before September 1, 2026?",
"rationale": "The main failure modes are a CRL or withdrawal; ruling these out supports a Yes.",
"weight": 0.3
},
{
"id": "sq3",
"question": "Has veligrotug\u0027s clinical/regulatory record (pivotal trial success, no safety holds) remained strong and on track?",
"rationale": "Strong Phase 3 data and clean regulatory status increase approval odds; weak signals would raise CRL risk.",
"weight": 0.2
}
],
"tool_requests": [
{
"parameters": {
"brief": "Latest status of Viridian Therapeutics veligrotug (VRDN-001) BLA for thyroid eye disease: FDA Priority Review, June 30 2026 PDUFA date, any approval, CRL, advisory committee, or delay news. Also clinical trial THRIVE results and safety.",
"max_searches": 4,
"question_title": "Will FDA approve veligrotug for thyroid eye disease before September 1, 2026?"
},
"target_sub_questions": [
"sq1",
"sq2",
"sq3"
],
"tool_name": "claude_news"
},
{
"parameters": {
"lookback_days": 120,
"queries": [
"Viridian veligrotug FDA approval thyroid eye disease",
"veligrotug VRDN-001 PDUFA Complete Response Letter",
"Viridian Therapeutics BLA thyroid eye disease 2026"
]
},
"target_sub_questions": [
"sq1",
"sq2",
"sq3"
],
"tool_name": "article_search"
},
{
"parameters": {
"company_names": [
"Viridian Therapeutics"
],
"tickers": [
"VRDN"
]
},
"target_sub_questions": [
"sq3"
],
"tool_name": "earnings_data"
},
{
"parameters": {
"code": "import numpy as np\n# Base rate: Priority Review BLAs approval rate ~ high, often 85-90% for accepted applications with strong Phase 3 data\n# Probability approval occurs on/before PDUFA (June 30 2026) and before Sept 1 2026 cutoff\np_approve_overall = 0.88 # accepted BLA priority review with positive pivotal data\np_on_time_vs_delay = 0.85 # chance not pushed past Aug 31 if approved\np = p_approve_overall * p_on_time_vs_delay\nprint(\u0027Estimated approval before Sept 1 2026:\u0027, round(p,3))",
"description": "Base-rate estimate for Priority Review BLA approval before the cutoff date."
},
"target_sub_questions": [],
"tool_name": "code_execution"
}
]
},
"question": {
"close_time": "2026-06-19T09:00:00Z",
"description": "## Description\nViridian [says](https://investors.viridiantherapeutics.com/news/news-details/2025/Viridian-Therapeutics-Announces-BLA-Acceptance-and-Priority-Review-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease/default.aspx?utm_source=chatgpt.com) FDA accepted the veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date. A similar TED approval resolved publicly when FDA approved Tepezza, the first treatment for thyroid eye disease, in January 2020.\n\n`{\"format\": \"bot_tournament_question\", \"info\": {\"hash_id\": \"4f4f194d04ce2123\", \"sheet_id\": \"46\"}}`\n\n## Resolution Criteria\nThis question resolves as Yes if FDA approves veligrotug, VRDN-001, or the same active biologic for any thyroid eye disease indication before September 1, 2026. It resolves as No if FDA issues a CRL, the application is withdrawn, or no approval is publicly confirmed before September 1, 2026.",
"question_type": "binary",
"title": "Will FDA approve veligrotug for thyroid eye disease before September 1, 2026?"
},
"research": {
"cross_market_brief": "## Cross-Market Signals\n\n### Polymarket\n- \"Will Russia capture all of Stepnohirsk by September 30, 2026?\" \u2192 Yes: 0.11, Volume: $354.5K",
"errors": [],
"has_cross_market": true,
"n_errors": 0,
"n_tools": 4,
"tools": [
{
"elapsed_s": 34.65,
"error": null,
"success": true,
"summary": "10 citations",
"tool_name": "claude_news"
},
{
"elapsed_s": 0.62,
"error": null,
"success": true,
"summary": "26 articles",
"tool_name": "article_search"
},
{
"elapsed_s": 0.58,
"error": null,
"success": true,
"summary": "ok",
"tool_name": "earnings_data"
},
{
"elapsed_s": 0.0,
"error": null,
"success": true,
"summary": "Base-rate estimate for Priority Review BLA approval before t",
"tool_name": "code_execution"
}
]
},
"synthesis": {
"evidence": [
{
"claim": "Viridian says FDA accepted veligrotug BLA with Priority Review and set a June 30, 2026 PDUFA target action date.",
"credibility": 88,
"direction": "UP",
"priced_in": true,
"recency": "DATED",
"source": "article_search",
"strength": "STRONG",
"sub_question_id": "sq1"
},
{
"claim": "Tepezza was the first FDA-approved TED treatment (Jan 2020), establishing an approval pathway and validated mechanism for this indication.",
"credibility": 80,
"direction": "UP",
"priced_in": true,
"recency": "DATED",
"source": "description",
"strength": "MODERATE",
"sub_question_id": "sq3"
},
{
"claim": "FDA Commissioner Marty Makary is resigning after a rocky 13-month tenure amid management complaints.",
"credibility": 78,
"direction": "NEUTRAL",
"priced_in": false,
"recency": "RECENT",
"source": "article_search",
"strength": "MODERATE",
"sub_question_id": "sq2"
},
{
"claim": "FDA watchers warn of \u0027chaos,\u0027 staff hemorrhaging, and risk of regulatory delays inside the agency.",
"credibility": 65,
"direction": "DOWN",
"priced_in": false,
"recency": "RECENT",
"source": "article_search",
"strength": "MODERATE",
"sub_question_id": "sq2"
},
{
"claim": "FDA denied or discouraged at least eight drugs in the past year per RTW Investments, citing evidence concerns.",
"credibility": 68,
"direction": "DOWN",
"priced_in": false,
"recency": "RECENT",
"source": "article_search",
"strength": "MODERATE",
"sub_question_id": "sq2"
},
{
"claim": "No article specifically referencing veligrotug clinical trial data, safety holds, or regulatory status was found in the research set.",
"credibility": 40,
"direction": "NEUTRAL",
"priced_in": false,
"recency": "VERY_RECENT",
"source": "article_search",
"strength": "WEAK",
"sub_question_id": "sq3"
},
{
"claim": "No news of veligrotug approval, CRL, or delay appeared in articles through June 19, 2026.",
"credibility": 45,
"direction": "NEUTRAL",
"priced_in": false,
"recency": "VERY_RECENT",
"source": "article_search",
"strength": "WEAK",
"sub_question_id": "sq1"
}
],
"information_gaps": [
"No base rate for on-time PDUFA approval under Priority Review",
"No veligrotug pivotal trial (THRIVE) efficacy/safety results",
"No FDA advisory committee scheduling info for veligrotug",
"No confirmation of approval/CRL after June 30 PDUFA date"
],
"key_uncertainties": [
"Whether FDA staff turnover causes a delay past Sept 1",
"CRL risk given recent FDA rejection streak",
"Impact of Makary departure on review timelines",
"Whether manufacturing/inspection issues arise"
],
"n_evidence": 7
},
"timings": {
"forecast": 15.55,
"plan": 23.82,
"research": 34.65,
"synthesis": 13.22
}
}